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Abstract
Background: Viral hepatitis is a major concern worldwide, with hepatitis A (HAV) and E (HEV) viruses showing
sporadic outbreaks while hepatitis B (HBV) and C (HCV) viruses are associated with chronic hepatitis, cirrhosis and
hepatocellular carcinoma. The present study determined the proportion, geographic distribution and molecular
characterization of hepatitis viruses among patients seeking medical services at hospitals throughout Kenya.
Methods: Patients presenting with jaundice at four selected hospitals were recruited (n = 389). Sera were tested
for the presence of antibody to hepatitis viruses A through E, and HBV surface antigen (HBsAg). Nucleic acid from
anti-HAV IgM antibody and HBsAg positive samples was extracted, amplified and sequenced.
Results: Chronic HBV infection was the leading cause of morbidity among patients with symptoms of liver disease
seeking medical help. Incident HCV, HEV and HDV infection were not detected among the patients in this study, while
the proportion of acute HAV was low; HAV IgM positivity was observed in 6.3 % of patients and sequencing revealed
that all cases belonged to genotype 1B. HCV seropositivity upon initial screening was 3.9 % but none were confirmed
positive by a supplementary immunoblot assay. There was no serological evidence of HDV and acute HEV infection
(anti-HEV IgM). HBsAg was found in 50.6 % of the patients and 2.3 % were positive for IgM antibody to the core
protein, indicating probable acute infection. HBV genotype A was predominant (90.3 %) followed by D (9.7 %) among
HBV DNA positive specimens. Full genome analysis showed HBV/D isolates having similarity to both D4 and D6
subgenotypes and D/E recombinant reference sequences. Two recombinant sequences demonstrated > 4 %
nucleotide divergence from other previously known D/E recombinants.
Conclusions: HBV is highly prevalent among patients seeking care for symptoms consistent with hepatitis, compared
to the general population. Molecular characterization of HBV isolates indicated recombinant strains that may give rise
to new circulating variants. There is a need to document the prevalence, clinical manifestation and distribution of the
variants observed. HAV genotype 1B, prevalent in Africa, was observed; however, the absence of HCV, HDV and acute
HEV in this study does not rule out their presence in Kenya.
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Background
Viral hepatitis is a serious public health problem world-
wide. There are five main hepatitis-causing viruses desig-
nated A-E. Hepatitis A and E viruses (HAV, HEV) are
often asymptomatic but can also result in acute disease
often characterized by jaundice. They are transmitted
primarily through a fecal oral route and are common in
areas with sanitation challenges. HEV is responsible for
sporadic hepatitis epidemics in Kenyan refugee camps
[1]. Hepatitis B, C, and D viruses (HBV, HCV, and
HDV) are transmitted mainly through body fluids, and
often result in chronic liver infection. HBV is genetically
classified into ten genotypes (A-J), most having subgeno-
type groupings, based on full genome divergence of
>4.0 % but <7.5 %. HBV genotypes and subgenotypes
have a global geographic distribution pattern [2]. Subge-
notype A1 is predominant in Southern, Central and
Eastern Africa [3–7]. Quasi subgenotype HBV/A3, previ-
ously HBV/A3, A4, and A5 [2], is found in West Africa
and Haiti [8, 9]. Genotype D predominates in South
America, the Mediterranean region and Eurasia [10].
Current systematic analysis of genotype D subgenotypes
suggests that there are six subgenotypes, designated D1-
D6, with several genotype D recombinants observed
throughout Asia and Africa [11, 12]. HBV genotype E
(HBV/E) is confined to West, Central and North Eastern
Africa [5, 13]. It has low genetic diversity with no identi-
fied subgenotypes but it is often associated with recom-
binant variants including genotypes D and A. Kenya is a
large country at the geographical junction of the distri-
bution of the three HBV genotypes A, D and E; however,
little is known about the molecular diversity of HBV in
Kenya apart from analysis of the basal core promoter/
precore (BCP/PC) and partial preS2/S regions [6, 7, 14].
HCV prevalence in Kenya has been reported to be
approximately <1 % to 4.4 % in blood donors and
patients attending clinics, respectively [15]; however,
these data are based only on screening without further
confirmatory testing by PCR or immunoblot assays. This
prevalence is much lower than that reported among
HIV-infected patients (6 %) and injection drug users
(22 %) [16, 17].
In general, there is limited updated seroprevalence
data on HAV, HEV, HDV, confirmed HCV and their
disease burden in Kenya. The present study aimed to de-
termine the prevalence and molecular characteristics of
viral hepatitis A through E among patients with jaundice




Serum samples were obtained from 389 patients present-
ing with jaundice at four selected hospitals in Kenya. The
hospitals were Kenyatta National Hospital (Nairobi), Moi
Teaching and Referral Hospital (Eldoret), New Nyanza
Provincial General Hospital (Kisumu), and Coast General
Hospital (Mombasa). The hospitals were selected based on
the high number of attendees in that region. Patients were
enrolled prospectively from January-2012 to April-2013,
based on their presentation of jaundice at the four hospi-
tals, with no previous diagnosis of viral hepatitis based on
patient recollection and hospital records. The study was
designed to be a seroprevalence study performed on sam-
ples received in these hospitals for investigation of sus-
pected viral hepatitis, such that all patients presenting with
an observable jaundice condition, regardless of time of
onset and duration, within the given study period were eli-
gible for inclusion. At each hospital, individuals were
triaged for suspected viral hepatitis following presentation
of jaundice and in some cases other symptoms consistent
with liver involvement such as abdominal tenderness or
swelling, according to national guidelines for treatment of
Hepatitis B and C virus infections [18]. Prior to any hospital
testing, 4 mL whole blood was collected from study partici-
pants together with age and gender data. Following whole
blood processing, approximately 1 mL serum was available
for serological and molecular testing. Due to resource limi-
tations and the requirement for test or procedure fees from
patients [19], biochemical marker (ALT or AST) test results
were largely not available for this patient subset or could
not be accessed thereafter due to a lack of matching nom-
inal data. The study population included individuals aged
15 years or above, thus, the only exclusion criteria was age
<15 years. The minimum dataset provided with each speci-
men was gender and age.
Ethical approval and consent
Ethical approval was obtained from the Kenya Medical
Research Institute’s National Ethical Review Committee,
approval number SSC 2436. Further approval was given
by each participant or guardian through a signed con-
sent form prior to drawing a blood sample and obtaining
age and gender information.
Viral hepatitis screening methods
The 389 specimens collected were simultaneously tested
in different batches for HCV and HEV, followed by HAV
testing, HBV testing and finally HDV testing of HBsAg
positive specimens, based on our priority interests to
obtain prevalence information for hepatitis viruses in
Kenya that were lacking in the literature. Thus, antibody-
confirmed HCV and HEV prevalence were a top priority,
followed by HAV and lastly HBV/HDV. HAV and HBV
were given lower priority as there are several high-quality
literature references describing HAV and HBV prevalence
among different Kenyan populations.
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Serological and molecular analysis
Hepatitis A virus (HAV)
Sera were tested for the presence of IgM antibody to
HAV using the International Immunodiagnostics HAV-
IgM Ab EIA kit (International Immunodiagnostics Inc.,
California, USA). Nucleic acid was extracted from all
samples that were screened positive for HAV antibody.
HAV RNA was extracted using the NucliSENS easy
MAG total nucleic acid automated extraction system
(BioMerieux, Quebec, Canada). HAV amplification was
performed by nested PCR using primers listed in Table 1
in a One Step RT-PCR reaction. The PCR mixture con-
tained 1.75U Expand High Fidelity polymerase (Roche
Diagnostics), 250 μM dNTPs (Thermo Fisher Scientific),
20 μM reverse and forward primers, 1X High Fidelity
buffer, and 5 μl of the extracted RNA in a total volume
of 50 μl. After the first round, 5 μl was used for the 2nd
round nested reaction using a PCR mixture as above
with nested primers (F2/R2). The primers were based on
M14707 Hepatitis A wild type sequence [20].
Hepatitis B virus (HBV)
Hepatitis B surface antigen and antibodies to Hepatitis B
core antigen were analyzed by electrochemiluminescence
EIA using the COBAS e411 platform (Elecsys; Roche
Diagnostics, Quebec, Canada). Nucleic acid was extracted
from all samples that were screened positive for HBsAg.
HBV DNA from HBsAg positive samples was extracted
using the QIAamp® DNA blood mini kit (Qiagen Inc.,
Ontario, Canada). Two hundred microliters (200 μl) of the
sample was extracted as instructed in the user manual.
The extract was eluted in 60 μl nuclease free water
(Ambion®, Thermo Fisher Scientific, Massachusetts, USA).
Five microliters (5 μl) of the HBV extract was amplified in
a nested PCR. Two different sets of primers were used to
target the HBsAg (S1) and BCP/PC region (EP1-2; Table 1)
in a total volume of 50 μl per tube. Each tube contained
buffers, 20 μM forward and reverse primers, 2.5U Ampli-
taq Gold polymerase (Thermo Fisher Scientific) and
1.25 mM dNTPs. Full length HBV genome analysis was
carried out by amplification using published primers [21].
The PCR reaction conditions for both the HBsAg and
BCP/PC regions were 94 °C for 10 min, 40 cycles of 94 °C
for 30 s, 55 °C for 30 s and 72 °C for 40 s and final exten-
sion of 72 °C for 5 min. The amplicons were viewed
following electrophoresis on a 2 % agarose gel and any
PCR negative sample was re-amplified by nested PCR.
Five micro-liters of the 1st stage PCR amplicons were
used for the second amplification using S2 and C2 primers
for HBsAg and BCP/PC, respectively. The master mix and
the PCR profile were similar to the first round. All 1st and
2nd round amplicons were gel-purified prior to sequen-
cing and the sequences were treated as previously de-
scribed by Kowalec et al., [21].
Hepatitis C virus (HCV)
Antibodies to HCV were measured using the VITROS
ECiQ platform (Ortho Clinical Diagnostics, Ontario,
Canada) with confirmation of positive results performed
using the INNO LIA HCV Score assay (Fujirebio, Ghent,
Belgium) and HCV Real-time PCR. Nucleic acid was
extracted from all samples that were initially screened
positive for HCV antibody. HCV RNA was extracted using
the NucliSENS easy MAG total nucleic acid automated
extraction system (BioMerieux, Quebec, Canada). HCV
Real-time PCR was performed as previously described
[22].
Hepatitis D virus (HDV)
Antibodies to HDV were tested using the International
Immunodiagnostics HDV Ab EIA kit (International Im-
munodiagnostics Inc., California, USA).
Hepatitis E virus (HEV)
Sera were tested for the presence of IgG and IgM anti-
bodies to HEV using commercial ELISA assays (Wantai,
Beijing, China).
Sequencing the isolates
All PCR positive amplicons were purified using the
Qiagen Gel purification kit according to the manufac-
turers recommended protocol. Purified DNA was quan-
tified with Nanodrop (Thermo Fisher Scientific), and
purified DNA (50 ng) was then sequenced using an au-
tomated ABI 3750 XL Genetic Analyzer (Thermo Fisher
Scientific). Amplification primers (Table 1) were used for
sequencing. Directly amplified sequences were assem-
bled and analysed using DNA sequence analysis software
(Lasergene software suite v7.1.0, DNASTAR). Sequences
Table 1 Primers used for amplification of HAV and HBV
Virus to be amplified Primer Name Sequence (5′–3′)
HAVa HAV F1 GACAGATTCTACATTTGGATTGGT
HAV R1 CCATTTCAAGAGTCCACACACT
nested HAV F2 CTATTCAGATTGCAAATTACAAT







nested C2 (EP3) CATAAGAGGACTCTTGGACT
nested C2 (EP4) GGCAAAAAAGAGAGTAACTC
a[20]; b[53, 54]
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were aligned and edited separately using ClustalX v2.0.1
[23] and Bio-Edit software [24], respectively.
Phylogenetic analysis
Maximum Likelihood phylogenetic analyses of the HBV
surface antigen-coding region (681 bp; nt 155–835) and
the HBV BCP/PC region (307 bp; nt 1653–1959) were
performed using the Kimura 2-parameter + γ substitution
model as the most appropriate model, and neighbor-
joining tree construction with 500 bootstrap replicates
was performed by MEGA v.5.2 [25].
Full length HBV genome phylogenetic analysis was per-
formed by the GTR+ γ + I model as described above.
Nucleotide pairwise distance of HBV genotype D full gen-
ome sequences was measured using DIVEIN software by
the GTR+ γ + I substitution model [26]. Mutations were
analyzed in the BCP/PC and HBsAg surface regions by
alignment with genotype reference sequences.
Intergenotypic recombination analysis of suspect re-
combinant sequences was performed using SSE v1.1 [27]
with a set of 295 GenBank reference sequences (available
upon request).
HBV full genome and HAV partial genome sequences
obtained in this study were submitted to the National
Center for Biotechnology Information GenBank database
[KP168416 to KP168435; KT723433 to KT723437].
Statistical analysis
The data was analyzed using statistical software (SPSS
v.16.0). Fisher’s exact test was used to analyze associa-
tions between age and geographical region among HBV
genotypes, the 2-tailed Z-test at 95 % significance was
used to compare HAV prevalence among regions, and
the Student’s T test was used to analyze differences in
mean age based on HBsAg positivity. A P value of <0.05
was considered significant.
Results
Patient population demographic profile
Three hundred and eighty nine (389) blood samples
were collected from patients presenting with jaundice
at four selected hospitals in Kenya. These samples in-
clude 245 from Nairobi city and its surroundings (KN),
76 samples from Kisumu (KSM), 40 samples from
Mombasa (MBS) and 28 from Eldoret (ELD). Screening
for HCV antibody was conducted on 388 samples, while
385, 382, and 332 samples were screened for HEV,
HAV and HBV, respectively, as sample volumes became
exhausted. Figure 1 illustrates the testing performed for
each hepatitis virus among the study specimens and the
subsequent results as a flow chart. The mean age (±
SD) of patients from each region was as follows; KN
39.8 years (±14.1), KSM 35.2 years (±11.9), MBS
36.2 years (±12.3), ELD 32.1 years (±10.4). The male to
female ratio was 4:3. Table 2 shows the prevalence of
each detectable hepatitis virus according to gender and
region, as well as the mean age (± SD) and overall
prevalence ± 95 % confidence intervals (CI) and propor-
tion for each detectable hepatitis virus
HAV
Twenty-four out of 382 (6.3 % ± 2.43 %, 95 % CI) sam-
ples were anti-HAV IgM positive. Based on their area of
residence, most incident cases were from Kisumu (7/76
= 9.2 %), followed by Nairobi (15/238 = 6.3 %) and Mom-
basa (2/40 = 5.0 %); however, no significant prevalence
differences were observed between regions (p > 0.05).
None of the 28 patients from Eldoret had evidence of
acute HAV infection. The majority of infected persons
were 20–49 years of age, with a prevalence of 6.5 % ±
2.83 %, 95 % CI. Stratified age group analysis showed
that most affected males were in the 20–29 year age
group (43.8 %) while females were most affected in the
30–39 year age group (37.5 %). Most cases in the cities
of Nairobi and Mombasa belonged to the 20–29 year
age group while in Kisumu most of those infected were
40–49 years of age. Five patients (1.3 %) were found to
have HAV/HBV co-infection; three from Kisumu, one
from Nairobi and the other from Mombasa. Five of 24
samples were RNA positive. Phylogenetic results from
these five isolates revealed that they were all genotype
1B [GenBank: KT723433 to KT723437].
HBV
Screening for hepatitis B virus surface antigen (HBsAg)
was performed with 332 individual samples from the 4
clinic sites. Out of the 332 samples, 168 were HBsAg
positive (50.6 % ± 5.38 %, 95 % CI). IgM antibody to the
core protein (anti-HBc IgM) was tested in 128 out of
the 168 HBsAg positive of which 3 (2.3 %) were
positive, indicating possible acute infection or acute
exacerbation of chronic hepatitis. Based on the area of
residence, Eldoret had the highest proportion of HBsAg
positive cases, 26/28 (92.9 %), followed by Mombasa,
9/11 (81.8 %), Kisumu, 59/74 (79.8 %), and Nairobi,
74/219 (33.8 %). The mean age (± SD, range) for
those HBsAg positive was not significantly different
(p = 0.053) from those HBsAg negative, at 36.5 years
(±11.2, 16–64 years) vs. 39.4 years (±15.7, 15–85
years), respectively. A male to female ratio of 2:1 was
observed for HBsAg positive individuals. One-
hundred and thirty-nine HBsAg positive samples hav-
ing sufficient volume for further testing were ex-
tracted for HBV DNA, with 93 (66.9 %) successfully
amplified for either the HBV surface region (N = 86),
and/or the BCP/PC region (N = 79). Twenty samples
chosen at random were amplified for full genome
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sequencing. HBV genotype A predominated (90.3 %)
followed by genotype D (9.7 %).
HCV
Initial screening of 388 samples for antibody to HCV by
chemiluminescent immunoassay resulted in 15 initially
reactive specimens (3.9 %). However, upon confirmatory
testing by INNO-LIA HCV Score immunoblot assay, all
specimens were negative for HCV antibody, with the
exception of 3 indeterminate INNO-LIA results. None
of the 15 samples were found to be positive for HCV
RNA by Real-time PCR.
Table 2 Mean age and prevalence of viral hepatitis according to gender and regiona
HAV HBV HEV
Age; mean ± SD (range) 35.1 ± 15.3 (16–84) 36.5 ± 11.2 (16–64) 41.4 ± 14.5 (17–75)
Gender; % (proportion) Male; n = 218 66.7 % (16/24) 65.5 % (110/168) 45.2 % (14/31)
Female; n = 171 33.3 % (8/24) 34.5 % (58/168) 54.8 % (17/31)
Regionb; % (proportion) KN; n = 245 6.3 % (15/238) 33.8 % (74/219) 12.9 % (31/241)
KSM; n = 76 9.2 % (7/76) 79.8 % (59/74) 0 % (0/76)
MBS; n = 40 5.0 % (2/40) 81.8 % (9/11) 0 % (0/40)
ELD; n = 28 0 % (0/28) 92.9 % (26/28) 0 % (0/28)
Overall Prevalence ± 95 % CI (proportion) 6.3 % ± 2.43 % (24/382) 50.6 % ± 5.38 % (168/332) 8.1 % ± 2.72 % (31/385)
aThe overall prevalence of HCV (n = 388) and HDV (n = 168 HBsAg positive samples) was determined to be 0 %
bRegion codes are described in the Results
Fig. 1 A flow-chart detailing the viral hepatitis serological screening and molecular testing algorithm for specimens collected from individuals
presenting with jaundice at four Kenyan hospitals. The associated results for each group of specimens for each hepatitis virus are also shown
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HDV
No anti-HDV antibodies were detected among the 168
HBsAg positive samples.
HEV
The prevalence of IgG antibodies to HEV among patient
samples was 8.1 % ± 2.72 %, 95 % CI (31/385). None of the
specimens were anti-HEV IgM positive. More females
(54.8 % ± 17.52 %, 95 % CI) than males (45.2 % ± 17.52,
95 % CI) were exposed to HEV, based on IgG results.
Phylogenetic analysis of HBV isolates
Phylogenetic analysis of partial genome sequences showed
that HBV genotype A isolates clustered with sub-genotype
A1 reference sequences with a distinction noted between
the Asian A1 clade and the African A1 clade for HBsAg
region analysis. As shown in Fig. 2, isolates from all four
sites cluster with sequences from neighboring Tanzania,
Uganda, Rwanda, Congo, Zimbabwe and South Africa
(African A1 clade). The majority of isolates (>70.0 %) from
Nairobi and its environs clustered with Asian A1 se-
quences from the Philippines, Bangladesh, Somalia and
Japan (Fig. 2a). Based on HBsAg gene analysis, three geno-
type A sequences from Mombasa (MBS116, MBS117, and
MBS120) formed a distinct sub-cluster supported by 62 %
bootstrapping for 500 replicates by Maximum Likelihood
phylogenetic analysis.
Compared to HBV/A isolates, there was a statistically
significant difference observed in age and geographical
region with HBV/D isolates (Fisher test, p = 0.02). Patients
with genotype D (8/9) were mainly from the region of
western Kenya in Eldoret, while 1/9 genotype D speci-
mens was observed in Nairobi. All genotype D-infected
individuals were male with a mean age of 43.0 ± 2.0 years
whereas, individuals infected with genotype A had a mean
age of 34.0 ± 4.0 years.
Fourteen genotype A and six genotype D samples were
analyzed for full genome sequence in order to clarify
subgenotype determination (Fig. 3). The mean nucleotide
distance within the 14 genotype A full genome sequences
was 3.47 % ± 0.25 %, owing to the unusual sequence of
isolate MBS117; if excluded the mean distance is 2.71 %
±0.23 %. MBS117 had sequence characteristic of genotype
A; however, sequence alignment with all reference geno-
types showed that a region spanning approximately
nucleotides 2860 to 2953 within the PreS1 region had
nucleotide substitutions characteristic of genotype E, in-
cluding the 3 nucleotide deletion leading to loss of PreS1
amino acid 11.
Based on full genome phylogenetic analysis, four geno-
type D isolates, ELD416, ELD422, ELD429, and KN109,
clustered apart from reference HBV genotype D subgeno-
types, except GenBank accession number JQ927384, a
recently submitted genotype D6 strain from Kenya (Fig. 3).
ELD401 and ELD428 were also observed to cluster separ-
ately from all other genotype D subgenotypes. Nucleotide
distance measurements suggested that ELD416, ELD422,
and ELD429 had similar identity to subgenotypes D4 and
D6, but also D-E recombinant reference sequences,
compared to other subgenotypes of D, while KN109 had a
nucleotide distance identity falling within reference subge-
notype D6 sequences (Table 3). All genotype D isolates had
the signature amino acid rt237T, characteristic of D6 and
D/E recombinant sequences [11]. Full genome sequence
analysis of ELD401 and ELD428 demonstrated the lack of
the genotype D-specific 33 nt deletion following the PreS1
start codon, similar to the observation of Chekaraou et al.
[28]. ELD401 and ELD428 full genome sequences had a
nucleotide distance >4 % from all HBV/D subgenotypes
and D/E recombinant reference sequences, which is the
minimum requirement for a new subgenotype [2, 29].
HBV recombination analysis
As genotype D complete genome sequences did not read-
ily cluster with a specific subgenotype, or were found to
have a nucleotide distance >4 % from other subgenotypes,
recombination analysis was conducted using the Simmo-
nic software package (SSE v1.1). Recombination analysis
revealed that isolates ELD401 and ELD428 were putative
D/E recombinants (Fig. 4a and b) with ELD401 also dem-
onstrating a grouping scan value approaching 50 % for
genotype A recombination at nucleotide positions 1840 to
2240 (Fig. 4a). Genotype E recombination was observed
within the preS1 region (nt 2800–3000) with both se-
quences, similar to previously described D/E recombinant
isolates [28], although both ELD401 and ELD428 had
>4 % nucleotide distance from recombinant sequences
deposited in GenBank [FN594769, FN594770, FN594771].
Recombination was also investigated with ELD416,
ELD422, ELD429 and KN109 full genome sequences,
but all were determined to be genotype D sequences
without evidence of recombination. The grouping scan
analysis of genotype A specimen MBS117 showing pu-
tative recombination with genotypes D and E is shown
in Fig. 4(c).
Profiling mutations in the HBV genome
BCP/PC region substitutions A total of 79 DNA posi-
tive samples had sequence available to analyze substitu-
tions within the BCP/PC region (70 genotype A and 9
genotype D sequences). The percentage of select muta-
tions within this region is shown in Table 4. Five geno-
type A isolates either had a 1 nt deletion mutation at
nucleotide 1825, a 1 nt insertion at nucleotide 1838, or
a 13 nt insertion at nucleotide 1915. The precore stop
codon mutation, A1896, was identified in 4.3 % (3/70)
genotype A samples and 44 % (4/9) of genotype D
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samples. A1896 co-existed with T1858 in genotype A
sequences, and all HBV/D strains were found to have
T1858. The double mutation T1762/A1764 was ob-
served with both genotype A and D sequences. A total
of 23 (33 %) HBV/A and 4 (44 %) HBV/D isolates had
the double BCP mutation or a variation of it (T1762/
G1764 or A1762/A1764).
The substitutions characteristic of subgenotype A1 [4]
were highly prevalent among study isolates. The G1809T,
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Fig. 2 Phylogenetic analysis of Kenyan HBV subgenomic sequences. Specimen codes are described in the Results. Maximum likelihood analysis
and neighbor-joining tree construction with 500 bootstrap replicates was performed by the K2 + γ model by MEGA v.5.2. Comparative GenBank
sequences are designated by the subgenotype followed by the accession number and country of origin. Bootstrap confidence values ≥60 % are
shown. a HBsAg (681 bp; nt 155 – 835) (b) BCP/PC region (307 bp; nt 1653–1959)
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Fig. 3 (See legend on next page.)
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93 %, 10 %, and 89 % of genotype A sequences respect-
ively, with 5 of 7 sequences having a triple nt 1809–1812
mutation also having the T1762/A1764 mutation or a
variation of it. G1862T/C and G1888A mutations were
observed in 34 % and 67 % of genotype A sequences,
respectively (Table 4).
HBsAg-coding region substitutions A number of sub-
stitutions were observed in the antigenic determinant
region (amino acids 100–160) of the HBsAg coding
sequence from genotype A isolates; no HBsAg substitu-
tions were observed with genotype D sequences (Table 4).
Three isolates (KN202, KN207 and KN134) had the
mutation sM133I. Three different substitutions (sI110L,
sG112R, and sT114S) were observed in two different
isolates each. Two isolates (KSM561, KSM572) from the
same geographic area, had two substitutions (sG112R, and
sT114S). One isolate, KSM04, had four substitutions
(sM103I, sQ129R, sG130N, sP135H) within the antigenic
determinant region.
Discussion
This is the first publication describing the epidemio-
logical and molecular characterization of viral hepatitis
in Kenya in patients seeking medical care in different
hospitals. HBsAg positivity was identified in half of the
patients tested, with the majority having chronic infec-
tion and only 2.3 % presumably acutely infected based
on the detection of anti-HBc IgM positivity. Acute HAV
infection was detected in 6.3 % of tested patients; how-
ever, in the remaining patients, no laboratory markers of
HCV, HDV or HEV infection were detected.
HAV is endemic in areas with sanitation challenges
due to lack of control of transmission factors and pres-
ence of HAV in the environment [30, 31]. In our study,
HAV was observed in cities faced with overpopulation
and increases in high density substandard housing [32].
Lack of access to clean water and food could also be
contributing factors for HAV exposure. HAV genotype
1B which was responsible for acute infection in the
present study, is associated with water contamination
[31], thus further investigation is required to determine
if this is the main mode of transmission in the country.
Most of the previous studies on HAV in Kenya have
focused on the high prevalence rates in children; 43.7 %
[32] and 63.2 % [33]. Only one study, by Greenfield et
al. [34], reported a prevalence of 12 % among adults. A
number of studies have showed that by the age of
10 years, 90 % of children in areas where HAV is en-
demic have been infected with the virus [35, 36], thus
older children and adults are generally immune. The
prevalence observed in this study (6.3 %) was within the
age group of adults seeking medical services which was
unexpected; however, as sanitation improves in urban
areas, there could be a shift in the age of HAV suscep-
tible individuals from young children to adults [37].
HAV vaccine is available in leading hospitals in Kenya,
although its uptake is still low.
There are few reports on HCV, HDV and HEV infec-
tion in Kenya. Initial anti-HCV screening in the present
study indicated a prevalence of 3.9 %, comparable with
previous reports of Ilako et al., [38] at 2.6 %, Karuru et al.,
[15] at 4.4 % and Harania et al., [39] at 1.0 %, none of
which employed anti-HCV supplementary testing. Use of
(See figure on previous page.)
Fig. 3 Phylogenetic analysis of 20 Kenyan complete HBV genome sequences. Specimen codes are described in the Results. Maximum likelihood
analysis and neighbor-joining tree construction with 500 bootstrap replicates was performed by the GTR +ϒ + I model by MEGA v.5.2. Comparative
GenBank sequences are designated by the subgenotype followed by the accession number and country of origin. Bootstrap confidence values ≥60 %
are shown. The ruler shows the branch length for a pairwise distance equal to 0.05. The GenBank accession numbers for the sequences reported are
KP168416 to KP168435
Table 3 Mean pairwise nucleotide distances between genotype D subgenotypes and Kenyan complete genome genotype D
sequences
Genotype D subgenotypea
D1 D2 D3 D4 D5 D6 D-E
Genotype D full genome sequences ELD401 0.0612 0.0648 0.0613 0.0534 0.0688 0.0494 0.0488
ELD416 0.0405 0.0443 0.0382 0.0315 0.0467 0.0302 0.0329
ELD422 0.0430 0.0481 0.0425 0.0332 0.0512 0.0317 0.0333
ELD428 0.0543 0.0577 0.0535 0.0452 0.0612 0.0412 0.0423
ELD429 0.0412 0.0450 0.0389 0.0322 0.0474 0.0308 0.0335
KN109 0.0505 0.0534 0.0514 0.0445 0.0586 0.0389 0.0467
aGenBank reference sequences used were as follows: D1 (AF280817, AJ344116, AF151735, GU456684, AB104711), D2 (AY090453, X72702, GQ477453, JF754597,
AB078032), D3 (U95551, AY233296, AJ627217, EU921419, AB493846), D4 (HQ700500, AB033559, AB048703, FJ692533, HE974378), D5 (GQ205377, GQ205385,
GQ205389, AB033558, GQ205382), D6 (FJ904409, FJ904447, FJ904403, FJ904433, FJ904438, FJ904410, FJ904395, FJ904442, KF170740, JQ927384), D-E recombinant
(FN594771, FN594769, FN594770); values in bold represent nucleotide diversity >4 %
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Fig. 4 (See legend on next page.)
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confirmatory testing in the present study showed that all
suspect specimens were negative for HCV antibody, which
may indicate that previously reported data may include
false-positive results.
Previous reports on HDV prevalence in Kenya de-
scribed a low prevalence in most parts except northern
Kenya where the prevalence was 31 % [40]. Our study
found no specimens positive for HDV antibody, even
among samples from northern Kenya. This may be due
to differences in testing methods among the studies, or
it may be that rates of HDV infection have decreased
over time in Kenya. However, such a comparison must
be interpreted with caution, as although HBV prevalence
in Kenya is high, the absence of HDV detection does not
rule out its presence in the country.
To date there is limited data on the source and geno-
type of HEV in Kenya. Our study found no acute cases
of HEV as indicated by IgM positivity. However, a preva-
lence of 8.1 % anti-HEV IgG positivity indicates that the
virus is present in Kenya, albeit at a modest rate.
Kenya is considered endemic for hepatitis B infection
(>8.0 % HBsAg prevalence; [36]), and case rates appear
to be increasing [41]. Efforts to reduce transmission
through infant immunization and blood donor screening
have been promoted in the country; however, HBV
infection remains high [16, 42]. The highest number of
HBsAg positive cases were observed in western Kenya
(Eldoret) at 92.9 % followed by Mombasa at 81.8 %, with
other regions showing marked differences, such as
33.8 % HBsAg positivity in Nairobi, which was some-
what surprising. Bias may have been introduced in the
HBsAg prevalence estimate for Mombasa, as only one
quarter of specimens collected from the participating
hospital were tested for HBsAg, resulting in a very high
prevalence (81.8 %), which may not be representative of
the region. Nevertheless, almost 90 % of specimens from
the Kenyatta National Hospital in Nairobi, and 100 % of
specimens collected from the Moi Teaching and Referral
Hospital in Eldoret were tested for HBsAg positivity,
with marked differences observed between the two sites
(33.8 % vs. 92.9 %, respectively). As all patients were
symptomatic with jaundice, the differences in causality
may be due to differences in the patient population seek-
ing medical attention among regions. For example, a
previous investigation has shown a considerably higher
prevalence of HBsAg positivity in Eldoret (17.8 %) com-
pared to Nairobi (7.7 %) among pregnant women [43].
Alternatively, environmental or infectious agents other
than viral hepatitis associated with jaundice may be in-
volved, such as malaria and other parasitic infections.
For example, although both Nairobi and Eldoret are
located at higher altitudes having conditions thought to
be unfavorable for malarial transmission, Nairobi has
had recurrent epidemics in past decades [44] and ap-
pears to be presently in the midst of increasing malaria
incidence, partly due to climate change [45, 46]. These
past epidemics and the higher density urbanization of
Nairobi may result in increased malarial diagnostic
experience and resources relative to other regions of
intermediate malaria prevalence, such as Eldoret [47].
Similarly, a report of improved diagnostic capability for
malaria within an Eldoret clinic showed a significant
decrease in the number of confirmed malaria cases [48].
Kenya is a country at the geographical junction of the
distribution of the three common HBV genotypes in Africa,
A, D and E, which provides an opportunity to study the
diversity and interactions of these genotypes. In this study,
we successfully sequenced 93 samples from patients attend-
ing 4 hospitals throughout Kenya. Genotype A was the
major circulating genotype, followed by genotype D, which
(See figure on previous page.)
Fig. 4 Grouping Scan analysis of the complete genome of (a) ELD401 (b) ELD428 (c) MBS117. The complete genome was scanned against
GenBank reference sequences of human HBV genotypes A-H and chimpanzee- and gibbon-derived strains (n = 295 sequences). Association
values ≥0.5 indicate phylogenetic clustering with the specified genotype reference group, while those <0.5 indicate an outgroup position
having no phylogenetic association with the genotype reference groups
Table 4 Prevalence of HBsAg and BCP/PC mutations observed
among HBV genotype A and D sequences
Mutation (%)a
Nucleotide mutation Genotype A Genotype D
HBsAg amino acid substitutionsb 11/77 (14) 0
BCP/PC insertion/deletionsc 5/70 (7) 0
C1653T 2/70 (3) 3/9 (33)
A1752C 0 1/9 (11)
T1753V 3/70 (4) 2/9 (22)
A1762T/G1764Ad 23/70 (33) 4/9 (44)
G1809T 65/70 (93) 0
A1811T/C 7/70 (10) 0
C1812T 62/70 (89) 0
C1858T 4/70 (6) 9/9 (100)
G1862T/C 24/70 (34) 0
G1888A 47/70 (67) 0
G1896A 3/70 (4) 4/9 (44)
aGenotype A: 77 and 70 samples could be amplified for HBsAg and BCP/PC
sequences, respectively; Genotype D: Sequence was available in both regions
for all 9 samples. bThe following substitutions within the antigenic
determinant region (amino acids 100–160) of the HBsAg gene were observed:
M103I, L109P, I110L, G112R, T114S, T115A, T118K, Q129R, G130N, M133I,
F134I/V, P135H, T143M, S155R; csee text; dincludes A1762/A1764 (6 genotype
A and 2 genotype D) and T1762/G1764 (3 genotype A)
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was primarily observed in western regions of Kenya. Earlier
Kenyan studies had observed genotypes D and E, with both
subgenotypes D4 and D6 in circulation among blood donor
and liver patients, respectively [6, 7, 14]. In this study, sev-
eral recombinant HBV D/E variants were observed in west-
ern Kenya, with recombination breakpoints falling within
the preS coding region. Recombinants of HBV genotypes D
and E have been described in Northern Africa [13, 28, 49].
The recombinant variants observed in the present study
demonstrated nucleotide divergence >4.0 % compared to
previously reported strains, suggestive of a new subgeno-
type. Recombinant strains may develop following HBV
intergenotype dual infections [50] or may persist as a circu-
lating strain throughout a population. The clinical manifes-
tations of D/E recombinant strains are poorly documented.
A genotype A variant having putative recombination with
genotype E and/or D, collected from coastal Kenya, was
also observed within the study population. There are very
few reports of genotype A/E recombinants and therefore
their impact needs to be assessed.
Based on full genome analysis, most genotype D se-
quences shared identity with subgenotypes D4 and D6;
however, amino acid E161 of the polymerase terminal
protein, characteristic of D6 sequences, was only observed
with study sequences, as opposed to the subgenotype D4
signature V161 amino acid [11]. Similarly, all genotype A
samples in the study having sufficient sequence information
had amino acid signatures consistent with subgenotype A1
[4], and were found to have a low prevalence of HBsAg
immune escape mutations. The BCP double mutation,
T1762/A1764 was observed with both genotype A and D
isolates. This mutation has been commonly associated with
more severe clinical outcomes [51], although this study did
not investigate the association with severity of liver disease.
This study has some limitations. The use of specimens
from adults seeking medical care at major hospitals may
possibly bias prevalence estimates towards a higher value.
A further limitation is the possibility that patients chronic-
ally infected with HBV and having knowledge of their
HBV status were inadvertently included in the study
population, although every attempt was made to eliminate
symptomatic patients presenting for HBV management.
The lack of detection of acute viral hepatitis and/or viral
RNA may have been affected by the timing of specimen
collection relative to the date of symptom onset, if sam-
ples were collected during the post-viremic period.
Similarly, cases of acute HCV infection may have been
missed among the 373 patients testing negative for HCV
antibody, as these samples were not further tested for
HCV RNA. The low incidence of acute HBV infection
was somewhat unexpected; however, this observation was
likely due to some participants experiencing symptomatic
flares of chronic infection, for which they were diagnosed
for the first time. This observation may be related to
variable healthcare seeking behavior, particularly regarding
large hospital facilities, which has been described in Kenya
[52].
Conclusions
HBV is highly prevalent among patients seeking care at
Kenyan hospitals for symptoms consistent with hepatitis,
compared to the national HBV prevalence. Molecular
characterization of circulating HBV indicated recombinant
strains that may give rise to new circulating variants. There
is a need to document the prevalence, clinical manifestation
and distribution of the variants observed. HAV genotype
1B, prevalent in Africa, was observed within the study
population. The absence of HCV, HDV and acute HEV in
this study does not rule out their presence in Kenya.
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